Researchers at Weill Cornell Medicine and the Cornell University College of Veterinary Medicine have undertaken an ambitious $5 million project to create new model systems that accurately reflect the biology, genetics and tumor-host interactions of difficult-to-treat blood cancers. Read more
Thousands of hematologists gathered in San Diego on Dec. 3 for the 58th Annual Meeting of the American Society of Hematology (ASH), and Weill Cornell Medicine/NewYork-Presbyterian was well represented. Read more
Infectious complication rates following prostate biopsies continue to increase, despite decreased use of the procedures, according to Jim Hu, M.D. Read more
A multidisciplinary team led by Ithaca member Mingming Wu has devised a method for measuring the force a breast cancer cell exerts on its fibrous surroundings. Read more
Lipstick Angels, a non-profit that brings volunteer makeup artists into hospitals to treat them with facials, makeovers and massage treatments has started a program at NewYork-Presbyterian. Read more
An innovative clinical trial at Weill Cornell Medicine has helped Ralph Hills recover from an aggressive leukemia - without ever being admitted to the hospital. Read more
Findings from a highly anticipated, randomized, phase II trial could possibly pave the path for the FDA approval of the first targeted therapy for patients with triple-negative breast cancer (TNBC), explains Linda T. Vahdat, M.D. Read more
A team led by Doug Fearon, M.D., has traced cachexia to a molecular reprogramming of the liver induced by tumors, which also releases stress hormones that can prevent the immune system from responding. Read more
The metabolic state of patients influences their cancer risk, progression and response to treatment, warns researchers in the lab of Meyer director Lewis Cantley. Read more
